Amgen (AMGN) Invested Capital (2009 - 2026)

Amgen has reported Invested Capital for 18 years, with the latest figure at $74.4 billion in Q2 2026.

• On a quarterly basis, Invested Capital rose 12.65% year-over-year to $74.4 billion in Q2 2026; TTM through Jun 2026 was $74.4 billion, a 12.65% increase from a year earlier, with the FY2025 full-year figure at $67.9 billion, down 2.39% from the prior year.
• Invested Capital was $74.4 billion for Q2 2026 at Amgen, up from $72.0 billion in the prior quarter.
• The five-year high for Invested Capital was $74.4 billion in Q2 2026, with the low at $38.7 billion in Q1 2022.
• Average Invested Capital over 5 years is $63.8 billion, with a median of $68.7 billion recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Invested Capital dropped 12.38% in 2022, then surged 77.3% in 2023.
• Over 5 years, Invested Capital stood at $44.2 billion in 2022, then surged by 63.56% to $72.3 billion in 2023, then retreated by 3.82% to $69.5 billion in 2024, then slipped by 2.39% to $67.9 billion in 2025, then gained by 9.69% to $74.4 billion in 2026.
• The last three Invested Capital figures came in at $74.4 billion (Q2 2026), $72.0 billion (Q1 2026), and $67.9 billion (Q4 2025), per Business Quant data.